Search for a trial

MeninGene Recall study, substudy of the MeninGene study

1. Characterize the interplay between host factors and bacterial factors and the specific activation of inflammatory pathways.2. Evaluate the expression of identified risk genes after activation of inflammatory pathways in host immune mediating…

Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes

The primary objective of the study is the functional improvement with one point or more on the modified Rankin scale after the 12th week of natalizumab (compared to baseline).

A 96-week, prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib 4.5 mg/kg/day versus placebo in the treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis

The objective of the study is to compare the safety and efficacy of masitinib at 4.5 mg/kg/day or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day after three month of treatment versus placebo in the treatment of patients with…

HLA SUBTYPING IN ANTIBODY MEDIATED LIMBIC ENCEPHALITIS

Our aims are to analyse whether there is a specific HLA allele or allelic combination associated with susceptibility to LGI1 encephalitis, and to perform a pilot study with HLA subtyping in patients with encephalitis due to antibodies to Caspr2,…

Plegridy* (peginterferon β-1a) Real World Effectiveness and Safety Observational Program (POP)

This study will be conducted as a prospective, observational study of patients with relapsing forms of MS initiating treatment with Plegridy in routine clinical practice and patients who participated in Study 105MS302 or Study 105MS303. Enrolled…